Par Drugs (India) Investor Sentiment

PAR Stock   288.35  4.15  1.42%   
About 62% of Par Drugs' investor base is looking to short. The analysis of overall sentiment of trading Par Drugs And stock suggests that many investors are alarmed at this time. The current market sentiment, together with Par Drugs' historical and current headlines, can help investors time the market. In addition, many technical investors use Par Drugs And stock news signals to limit their universe of possible portfolio assets.
Par Drugs stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Par daily returns and investor perception about the current price of Par Drugs And as well as its diversification or hedging effects on your existing portfolios.
  
over three weeks ago at news.google.com         
Breakout stocks to buy or sell FSL to Indian Bank Sumeet Bagadia recommends five shares to buy today...
Google News at Macroaxis
over a month ago at news.google.com         
Pharma stock jumps 12 percent after companys net profit increases 240 percent QoQ - Trade Brains
Google News at Macroaxis
over a month ago at news.google.com         
Par Drugs Standalone September 2024 Net Sales at Rs 34.66 crore, up 33.88 percent Y-o-Y - Moneycontr...
Google News at Macroaxis
over a month ago at news.google.com         
Is Par Drugs and Chemicals Limiteds Recent Stock Performance Tethered To Its Strong Fundamentals - S...
Google News at Macroaxis
over two months ago at news.google.com         
Dont Ignore The Insider Selling In Par Drugs and Chemicals - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Lilly Gains in Obesity Race With Novo as Supplies Expand - Bloomberg
Google News at Macroaxis
over three months ago at news.google.com         
Par Drugs Standalone June 2024 Net Sales at Rs 22.61 crore, down 1.43 percent Y-o-Y - Moneycontrol
Google News at Macroaxis
over three months ago at news.google.com         
News Par Views Akums Drugs Pharmas IPO will open tomorrow, what is the business model of the company...
Google News at Macroaxis
over three months ago at news.google.com         
Endo recalls 1 lot of panic disorder drug due to labeling issue - FiercePharma
Google News at Macroaxis
over three months ago at news.google.com         
Gilead Stock Gains. Its Trying to Get Into the Obesity Drug Game. - Barrons
Google News at Macroaxis
over six months ago at news.google.com         
Declining Stock and Solid Fundamentals Is The Market Wrong About Par Drugs and Chemicals Limited - S...
Google News at Macroaxis
over six months ago at news.google.com         
Declining Stock and Solid Fundamentals Is The Market Wrong About Par Drugs and Chemicals Limited - S...
Google News at Macroaxis
over six months ago at news.google.com         
Structure Therapeutics Obesity-Drug Stock Has 80 percent Upside JPMorgan - Markets Insider - Markets...
Google News at Macroaxis
over six months ago at news.google.com         
Par Drugs Standalone March 2024 Net Sales at Rs 22.82 crore, down 6.83 percent Y-o-Y - Moneycontrol
Google News at Macroaxis
over six months ago at news.google.com         
Par Drugs Chemicals standalone net profit rises 7.83 percent in the March 2024 quarter - Business St...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Par Drugs that are available to investors today. That information is available publicly through Par media outlets and privately through word of mouth or via Par internal channels. However, regardless of the origin, that massive amount of Par data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Par Drugs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Par Drugs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Par Drugs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Par Drugs alpha.

Par Drugs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Is Par Drugs and Chemicals Limiteds Recent Stock Performance Tethered To Its Strong Fundamentals - Simply Wall St
10/17/2024
2
Breakout stocks to buy or sell FSL to Indian Bank Sumeet Bagadia recommends five shares to buy today Stock Market News - Mint
10/29/2024

Complementary Tools for Par Stock analysis

When running Par Drugs' price analysis, check to measure Par Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Par Drugs is operating at the current time. Most of Par Drugs' value examination focuses on studying past and present price action to predict the probability of Par Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Par Drugs' price. Additionally, you may evaluate how the addition of Par Drugs to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world